The rising price of insulin has become one of the most talked about issues across the pharma industry. Ben Hargreaves explains how Eli Lilly decided to cap its insulin price, why it has decided to ...

Despite recent legislation capping insulin prices and manufacturer assistance programs, some people with diabetes who require insulin still encounter barriers to obtaining a reliable supply.

Over the past decade, the rising cost of insulin epitomized the broader systemic issue of higher healthcare out-of-pocket costs that prevented many Americans from accessing essential care.

Last year, Eli Lilly, Novo Nordisk and Sanofi dropped their insulin prices between 65% to 80% ... Your support ensures our ...

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.

Biosimilar insulin glargine access in Europe correlates with significant price reductions of originator products, enhancing affordability and accessibility. The study observed a 21.6% average ...

Democratic Senator Scott Wiener from San Francisco recently resurrected a bill — now Senate Bill 40 — to cap insulin prices that Newsom vetoed last year. His veto message said CalRx made it ...

The Federal Trade Commission and the pharmacy benefit managers it's accusing of artificially inflating insulin prices are hitting a host of prominent companies, from McDonald's to the HR ...

Two years ago, California made a bold announcement that it would manufacture a state-branded, low-cost insulin. Drug manufacturers, insurers, economists and diabetics took notice. It had the ...